AstraZeneca Prepares For U.S. Statin Market Shake-Up As Lipitor Goes Generic
This article was originally published in The Pink Sheet Daily
Pricing pressure on AstraZeneca's Crestor expected from the arrival of generic atorvastatin in the U.S. in the fourth quarter.
You may also be interested in...
Clinicians recently took to the pages of the Journal of the American Medical Association to argue the appropriateness of using statin therapy as primary prevention in patients who are not already at high risk for a cardiovascular event. Such scrutiny comes as NIH prepares to issue new treatment guidelines to a market newly saturated with popular generic options, and as pharmaceutical companies assess how best to approach the dyslipidemia field.
PCSK9 inhibitors have come into vogue based on potent LDL-lowering in early studies. But the up-and-coming biologics still face questions about how they will fit in a market dominated largely by proven, oral generics.
The company isn’t providing much detail on reasons or commercial strategy going forward, but its long-term outlook, particularly in western markets, is uninspiring, burdened by generic competition and a mixed R&D track record.